An Open-Label, Multiple-Ascending Dose, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LSVT-1701 as an Add-on to Standard of Care Antibiotics for the Treatment of Complicated Methicillin-Sensitive and -Resistant Staphylococcus Aureus Bacteremia Including Left- and Right-sided Infective Endocarditis
Latest Information Update: 05 Jul 2022
At a glance
- Drugs Tonabacase (Primary)
- Indications Bacterial endocarditis
- Focus Adverse reactions
- Acronyms ERASE
- Sponsors Lysovant
- 28 Jun 2022 According to an iNtRON media release, Lysovant has made tens of million dollars investment for asset to receive the US Phase 2 IND approval
- 27 Jun 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 10 May 2022 Status changed from not yet recruiting to recruiting.